Clinical Trials Browser

Phase 2/3 × INDUSTRY × Imatinib Mesylate × Clear all

NCT02103322 2014-06-27

Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions

Phase 2/3 Completed

GastrointestinalMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gastrointestinal Stromal Tumors

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2/3 Terminated

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma